Institute of Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstaedter Landstrasse 1, D-85764 Neuherberg, Germany.
Br J Cancer. 2013 Nov 12;109(10):2714-23. doi: 10.1038/bjc.2013.625. Epub 2013 Oct 15.
MiR-221/-222 are frequently overexpressed in breast cancer and are associated with increased malignancy. The specific modification of microRNAs (miRNAs) expression could be a promising strategy in breast cancer therapy, leading to the suppression of tumourigenic processes in tumour cells.
MiR-221/-222 expressions were analysed in 86 breast cancer tissues by quantitative RT-PCR and tested for correlation with immunohistochemistry data and clinical follow-up. In vitro assays were conducted using human breast cancer cell lines with lentiviral overexpression of miR-221/-222.
In tumour tissues, miR-221/-222 were associated with the occurrence of distant metastases. In particular, high levels of miR-221 were revealed to have a high prognostic impact for the identification of significantly different groups with advanced tumours. MiR-221/-222 overexpression strongly increased cell proliferation and invasion in vitro. Following miR-221/-222 overexpression an increased uPAR expression and cell invasion were observed.
This study demonstrates a significant role for highly expressed miR-221/-222 in advanced breast cancers allowing for the identification of significantly different prognostic groups, particularly for HER2-positive and lymph-node-positive breast cancers. Considering that miR-221/-222 are strongly involved in cell invasion, these miRNAs may be promising markers for breast cancer prognosis and therapy.
miR-221/-222 在乳腺癌中经常过表达,并与恶性程度增加相关。微小 RNA(miRNA)表达的特异性修饰可能是乳腺癌治疗的一种有前途的策略,导致肿瘤细胞中肿瘤发生过程的抑制。
通过定量 RT-PCR 分析 86 例乳腺癌组织中的 miR-221/-222 表达,并检测其与免疫组织化学数据和临床随访的相关性。使用慢病毒过表达 miR-221/-222 的人乳腺癌细胞系进行体外实验。
在肿瘤组织中,miR-221/-222 与远处转移的发生有关。特别是,miR-221 的高水平显示出对识别具有显著不同的晚期肿瘤组的高预后影响。miR-221/-222 的过表达强烈增加了体外细胞增殖和侵袭。miR-221/-222 过表达后,uPAR 表达和细胞侵袭增加。
本研究表明高表达的 miR-221/-222 在晚期乳腺癌中具有显著作用,可识别具有显著不同预后组的患者,特别是 HER2 阳性和淋巴结阳性的乳腺癌。鉴于 miR-221/-222 强烈参与细胞侵袭,这些 miRNA 可能是乳腺癌预后和治疗的有前途的标志物。